Roche Quarterly Revenue Advances on Sales of Cancer Drugs

Roche Holding AG said third-quarter sales rose 2.7 percent, as demand for its main cancer medicines in the U.S. and China offset slower sales increases at its diagnostics division.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.